{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:40:52Z","timestamp":1791189652683,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"31","license":[{"start":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T00:00:00Z","timestamp":1450051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/onc.2015.472","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T11:02:38Z","timestamp":1450090958000},"page":"4036-4047","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression"],"prefix":"10.1038","volume":"35","author":[{"given":"C","family":"Duckworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S L","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S P","family":"Ethier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H W","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,14]]},"reference":[{"key":"BFonc2015472_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","volume":"164","author":"I-M Shih","year":"2004","unstructured":"Shih I-M, Kurman RJ . Ovarian tumorigenesis: a proposed model based on morphogical and molecular genetic analysis. Am J Pathol 2004; 164: 1511\u20131518.","journal-title":"Am J Pathol"},{"key":"BFonc2015472_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","volume":"4","author":"KR Cho","year":"2009","unstructured":"Cho KR, Shih Ie M . Ovarian cancer. Annu Rev Pathol 2009; 4: 287\u2013313.","journal-title":"Annu Rev Pathol"},{"key":"BFonc2015472_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609\u2013615.","journal-title":"Nature"},{"key":"BFonc2015472_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1073\/pnas.1311909111","volume":"111","author":"GP Dunn","year":"2014","unstructured":"Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci USA 2014; 111: 1102\u20131107.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015472_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1478-811X-7-22","volume":"7","author":"FU Wohrle","year":"2009","unstructured":"Wohrle FU, Daly RJ, Brummer T . Function, regulation and pathological roles of the Gab\/DOS docking proteins. Cell Commun Signal 2009; 7: 22.","journal-title":"Cell Commun Signal"},{"key":"BFonc2015472_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1158\/1541-7786.MCR-12-0352","volume":"10","author":"SJ Adams","year":"2012","unstructured":"Adams SJ, Aydin IT, Celebi JT . GAB2\u2013a scaffolding protein in cancer. Mol Cancer Res 2012; 10: 1265\u20131270.","journal-title":"Mol Cancer Res"},{"key":"BFonc2015472_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nm1341","volume":"12","author":"M Bentires-Alj","year":"2006","unstructured":"Bentires-Alj M, Gil SG, Chan R, Wang ZC, Wang Y, Imanaka N et al. A role for the scaffolding adapter GAB2 in breast cancer. Nat Med 2006; 12: 114\u2013121.","journal-title":"Nat Med"},{"key":"BFonc2015472_CR8","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1038\/sj.onc.1210315","volume":"26","author":"Y Ke","year":"2007","unstructured":"Ke Y, Wu D, Princen F, Nguyen T, Pang Y, Lesperance J et al. Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene 2007; 26: 4951\u20134960.","journal-title":"Oncogene"},{"key":"BFonc2015472_CR9","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1038\/onc.2012.367","volume":"32","author":"Y Yang","year":"2012","unstructured":"Yang Y, Wu J, Demir A, Castillo-Martin M, Melamed RD, Zhang G et al. GAB2 induces tumor angiogenesis in NRAS-driven melanoma. Oncogene 2012; 32: 3627\u20133637.","journal-title":"Oncogene"},{"key":"BFonc2015472_CR10","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/onc.2011.435","volume":"31","author":"Y Wang","year":"2012","unstructured":"Wang Y, Sheng Q, Spillman MA, Behbakht K, Gu H . Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells. Oncogene 2012; 31: 2512\u20132520.","journal-title":"Oncogene"},{"key":"BFonc2015472_CR11","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","volume":"23","author":"DA Altomare","year":"2004","unstructured":"Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23: 5853\u20135857.","journal-title":"Oncogene"},{"key":"BFonc2015472_CR12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/gcc.20883","volume":"50","author":"J Huang","year":"2011","unstructured":"Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R et al. Frequent genetic abnormalities of the PI3K\/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 2011; 50: 606\u2013618.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFonc2015472_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"Bast RC Jr, Hennessy B, Mills GB . The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415\u2013428.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2015472_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1158\/1535-7163.MCT-15-0039","volume":"14","author":"SJ Davis","year":"2015","unstructured":"Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S et al. Enhanced GAB2 expression is associated with improved survival in high-grade serous ovarian cancer and sensitivity to PI3K inhibition. Mol Cancer Ther 2015; 14: 1495\u20131503.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2015472_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","volume":"123","author":"K Behbakht","year":"2011","unstructured":"Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 123: 19\u201326.","journal-title":"Gynecol Oncol"},{"key":"BFonc2015472_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","volume":"30","author":"F Janku","year":"2012","unstructured":"Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM et al. PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012; 30: 777\u2013782.","journal-title":"J Clin Oncol"},{"key":"BFonc2015472_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ccr.2011.12.024","volume":"21","author":"T Muranen","year":"2012","unstructured":"Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC et al. Inhibition of PI3K\/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012; 21: 227\u2013239.","journal-title":"Cancer Cell"},{"key":"BFonc2015472_CR18","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/0008-5472.CAN-09-3912","volume":"70","author":"L Hernandez","year":"2010","unstructured":"Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM . Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res 2010; 70: 4005\u20134014.","journal-title":"Cancer Res"},{"key":"BFonc2015472_CR19","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1172\/JCI39065","volume":"119","author":"KA Charles","year":"2009","unstructured":"Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A et al. The tumor-promoting actions of TNF-a involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009; 119: 3011\u20133023.","journal-title":"J Clin Invest"},{"key":"BFonc2015472_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/jnci\/djn024","volume":"100","author":"WM Merritt","year":"2008","unstructured":"Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008; 100: 359\u2013372.","journal-title":"J Natl Cancer Inst"},{"key":"BFonc2015472_CR21","doi-asserted-by":"publisher","first-page":"16472","DOI":"10.1073\/pnas.0605752103","volume":"103","author":"G Yang","year":"2006","unstructured":"Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 16472\u201316477.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015472_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","volume":"150","author":"S Acharyya","year":"2012","unstructured":"Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150: 165\u2013178.","journal-title":"Cell"},{"key":"BFonc2015472_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1677\/ERC-10-0107","volume":"17","author":"C Bolitho","year":"2010","unstructured":"Bolitho C, Hahn MA, Baxter RC, Marsh DJ . The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr Relat Cancer 2010; 17: 929\u2013940.","journal-title":"Endocr Relat Cancer"},{"key":"BFonc2015472_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cyto.2012.04.013","volume":"59","author":"Y Wang","year":"2012","unstructured":"Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 2012; 59: 145\u2013155.","journal-title":"Cytokine"},{"key":"BFonc2015472_CR25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","volume":"22","author":"A Britschgi","year":"2012","unstructured":"Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U et al. JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012; 22: 796\u2013811.","journal-title":"Cancer Cell"},{"key":"BFonc2015472_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1172\/JCI39397","volume":"120","author":"C Ginestier","year":"2010","unstructured":"Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010; 120: 485\u2013497.","journal-title":"J Clin Invest"},{"key":"BFonc2015472_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10555-014-9538-9","volume":"34","author":"HJ Choi","year":"2015","unstructured":"Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK . Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev 2015; 34: 19\u201340.","journal-title":"Cancer Metastasis Rev"},{"key":"BFonc2015472_CR28","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ctrv.2011.06.004","volume":"38","author":"J Schmitt","year":"2012","unstructured":"Schmitt J, Matei D . Targeting angiogenesis in ovarian cancer. Cancer Treat Rev 2012; 38: 272\u2013283.","journal-title":"Cancer Treat Rev"},{"key":"BFonc2015472_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.imlet.2012.04.003","volume":"145","author":"M Allegretti","year":"2012","unstructured":"Allegretti M, Cesta MC, Garin A, Proudfoot AE . Current status of chemokine receptor inhibitors in development. Immunol Lett 2012; 145: 68\u201378.","journal-title":"Immunol Lett"},{"key":"BFonc2015472_CR30","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/ncomms3427","volume":"4","author":"CV Pecot","year":"2013","unstructured":"Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C et al. Tumour angiogenesis regulation by the miR-200 family. Nat commun 2013; 4: 2427.","journal-title":"Nat commun"},{"key":"BFonc2015472_CR31","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-10-0483","volume":"16","author":"G Yang","year":"2010","unstructured":"Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X et al. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010; 16: 3875\u20133886.","journal-title":"Clin Cancer Res"},{"key":"BFonc2015472_CR32","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.1073\/pnas.0804123105","volume":"105","author":"TL Yuan","year":"2008","unstructured":"Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci USA 2008; 105: 9739\u20139744.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015472_CR33","doi-asserted-by":"publisher","first-page":"8638","DOI":"10.1073\/pnas.1500722112","volume":"112","author":"MC Caino","year":"2015","unstructured":"Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A et al. PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proc Natl Acad Sci USA 2015; 112: 8638\u20138643.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2015472_CR34","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/2159-8290.CD-11-0046","volume":"1","author":"HW Cheung","year":"2011","unstructured":"Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 2011; 1: 608\u2013625.","journal-title":"Cancer Discov"},{"key":"BFonc2015472_CR35","doi-asserted-by":"publisher","first-page":"12372","DOI":"10.1073\/pnas.1109363108","volume":"108","author":"HW Cheung","year":"2011","unstructured":"Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA 2011; 108: 12372\u201312377.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2015472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2015472","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2015472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:58:54Z","timestamp":1684472334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2015472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,14]]},"references-count":35,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["BFonc2015472"],"URL":"https:\/\/doi.org\/10.1038\/onc.2015.472","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,14]]},"assertion":[{"value":"4 May 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}